Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment.

Recruiting N/A Interventional Study
Sarcoma Metastatic Locally Advanced Soft Tissue Sarcoma
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Supportive Care
Participants needed
377 (estimated)
Sponsor
Centre Oscar Lambret · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
ePPS-2202 is a study designed to evaluate the benefits of a dematerialised personalised care plan (PCP) compared to standard information/PCP for patients with advanced sarcomas receiving systemic treatment. Participants will be randomised to an experimental group or a control group. Patients in the experimental group will receive the dematerialised PCP in addition to the standard PCP while patien…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Sarcomas of soft tissues or viscera ; * Inoperable metastatic or locally advanced disease ; * Indication for systemic treatment with pazopanib, trabectedine, eribulin, ifosfamide or dacarbazine monotherapy ; * Patient covered by French social security ; * Written, signed, info…
Contacts

PANNIER Diane, DR

03.20.29.59.59

d-pannier@o-lambret.fr

CONTACT

THERY Julien, MD

J-THERY@o-lambret.fr

CONTACT